Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Fredun Pharmaceuticals approved the unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone net sales surged to Rs. 11,940.29 lakhs from Rs. 7,753.58 lakhs in Q1 FY25, a growth of about 54% year-on-year. Profit after tax rose to Rs. 676.58 lakhs from Rs. 412.99 lakhs, up roughly 64% YoY, with basic EPS at Rs. 14.33 versus Rs. 8.79. The statutory auditor R.H. Nisar & Co issued a limited review report with an unmodified (clean) conclusion on both standalone and consolidated results. Additionally, the Board appointed Mr. Anshu Agarwal and Ms. Sonal Desai as Non-Executive Independent Directors for a five-year term, subject to shareholder approval.
Strong topline and bottomline growth in Q1 FY26 is positive for shareholders and likely to be well-received by the market. The board strengthening with two new independent directors supports governance, though subject to shareholder ratification at the next general meeting.